Outcome of Board Meeting held today, i.e., 09th June, 2026 for approval of financial results for the half year and year ended 31st march, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.4 pts more than Nifty Microcap 250 and 10.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Goldline Pharmaceutical Ltd's Board approved standalone audited financial results for the half-year and full year ended 31st March 2026, along with appointment of M/s. Kunal Dutt & Associates as Internal Auditor from FY26-27. Revenue from operations grew ~11.2% YoY to Rs. 3,119.88 lakhs (vs Rs. 2,805.57 lakhs). Profit After Tax rose ~45% YoY to Rs. 411.71 lakhs (vs Rs. 283.43 lakhs), with EPS improving to Rs. 5.97 from Rs. 4.11. The statutory auditor (B Shroff & Co.) issued an unmodified opinion with an Emphasis of Matter noting the company's listing on BSE's SME platform on 19th May 2026, subsequent to the reporting period. Long-term borrowings declined sharply from Rs. 319.27 lakhs to Rs. 146.32 lakhs, while operating cash flow remained positive at Rs. 281.46 lakhs.
Strong profit growth and deleveraging signal improving financial health for the newly-listed SME company. Shareholders should note the auditor flagged the post-period listing as an emphasis matter, though the opinion remains clean with no qualifications.